CA
NZ
UK
AU
IND
US
…
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
NextCure, Inc. is a clinical-stage biotechnology company focused on developing immune-modulating therapies for oncology and other diseases. Its long-term growth drivers include advancement of its clinical-stage pipeline, validation through clinical trial outcomes and strategic collaborations that could support development and commercialization. Investors may find it attractive because the company appears positioned to deliver meaningful value if its biology and trials prove successful.
The company faces material risks from clinical trial failure, limited or no product revenue requiring additional financing, intense competition in immuno-oncology, and regulatory and execution uncertainty.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -74.73M | -69.39M | -36.60M | -33.74M | -22.80M |
| Minority interest | - | - | - | - | 0.00M |
| Net income | -69.43M | -69.39M | -33.19M | -33.74M | -22.80M |
| Selling general administrative | 21.71M | 20.57M | 17.05M | 9.61M | 3.41M |
| Gross profit | - | - | 22.38M | 6.35M | -19.79M |
| Reconciled depreciation | 4.12M | 7.20M | 3.41M | 2.69M | 1.68M |
| Ebit | -80.03M | -70.77M | -44.64M | -37.48M | -23.20M |
| Ebitda | -75.91M | -63.57M | -41.23M | -34.79M | -21.52M |
| Depreciation and amortization | 4.12M | 7.20M | 3.41M | 2.69M | 1.68M |
| Non operating income net other | 1.18M | 1.38M | 4.62M | - | - |
| Operating income | -75.91M | -70.77M | -41.23M | -37.48M | -23.20M |
| Other operating expenses | 75.91M | 70.77M | 63.60M | 43.83M | 23.20M |
| Interest expense | 5.30M | 1.38M | 0.00M | 0.00M | 0.00M |
| Interest income | - | - | - | 3.75M | - |
| Extraordinary items | - | - | - | - | 0.00M |
| Non recurring | - | - | - | - | 0.00M |
| Other items | - | - | - | - | 0.00M |
| Income tax expense | -5.30M | -1.38M | -3.41M | -3.75M | 0.40M |
| Total revenue | 0.00M | 0.00M | 22.38M | 6.35M | 0.00M |
| Total operating expenses | 75.91M | 70.77M | 63.60M | 43.83M | 23.20M |
| Cost of revenue | - | - | - | 34.22M | 19.79M |
| Total other income expense net | 1.18M | 1.38M | 4.62M | 3.75M | 0.40M |
| Discontinued operations | - | - | - | - | 0.00M |
| Net income from continuing ops | -74.73M | -69.39M | -36.60M | -33.74M | -22.80M |
| Net income applicable to common shares | -74.73M | -69.39M | -36.60M | -33.74M | -22.80M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 129.42M | 184.16M | 242.39M | 306.64M | 356.17M |
| Other current assets | 3.63M | 4.07M | 8.19M | 2.82M | 3.68M |
| Total liab | 15.00M | 16.63M | 9.00M | 12.92M | 34.68M |
| Total stockholder equity | 114.42M | 167.53M | 233.39M | 293.72M | 321.48M |
| Deferred long term liab | - | - | 2.39M | 0.79M | - |
| Other current liab | 3.90M | 4.34M | 4.67M | 4.76M | 4.95M |
| Common stock | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M |
| Capital stock | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M |
| Retained earnings | -324.48M | -261.76M | -187.03M | -117.64M | -81.03M |
| Other liab | - | 0.90M | 2.39M | 0.79M | 16.31M |
| Other assets | 0.00M | 3.27M | 0.58M | 2.86M | 4.08M |
| Cash | 13.08M | 26.63M | 12.34M | 32.77M | 34.09M |
| Total current liabilities | 6.88M | 9.13M | 6.61M | 10.32M | 15.04M |
| Current deferred revenue | - | - | - | - | 6.43M |
| Net debt | -6.48M | -19.51M | -12.34M | -29.30M | -28.96M |
| Short term debt | 0.66M | 0.52M | - | 1.67M | 1.80M |
| Short long term debt | - | - | - | 1.67M | 1.67M |
| Short long term debt total | 6.61M | 7.12M | - | 3.47M | 5.13M |
| Other stockholder equity | 439.10M | 430.75M | 421.05M | 410.55M | 46.36M |
| Property plant equipment | - | 11.90M | 13.99M | 15.81M | 12.09M |
| Total current assets | 112.72M | 163.98M | 227.82M | 287.98M | 340.00M |
| Net tangible assets | - | 167.53M | 233.39M | 293.72M | 321.48M |
| Short term investments | 95.22M | 133.28M | 207.25M | 250.68M | 300.51M |
| Net receivables | 0.80M | - | - | - | - |
| Long term debt | - | - | - | 1.81M | 3.33M |
| Accounts payable | 2.33M | 4.27M | 1.94M | 3.90M | 1.86M |
| Accumulated other comprehensive income | -0.22M | -1.49M | -0.66M | 0.78M | -0.04M |
| Common stock total equity | - | 0.03M | 0.03M | 0.03M | 0.03M |
| Retained earnings total equity | - | -261.76M | -187.03M | -117.64M | - |
| Non currrent assets other | 1.88M | 3.27M | 0.58M | 2.86M | 4.08M |
| Non current assets total | 16.69M | 20.18M | 14.57M | 18.67M | 16.17M |
| Capital lease obligations | 6.61M | 7.12M | - | - | 0.14M |
| Long term debt total | - | - | - | 1.81M | 3.33M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 67.98M | 38.96M | 50.66M | -303.92M | -300.55M |
| Change to liabilities | 2.33M | -2.14M | 1.80M | -4.97M | 28.07M |
| Total cashflows from investing activities | 67.98M | 36.60M | 43.52M | -303.92M | -3.06M |
| Net borrowings | - | -3.47M | -1.53M | 4.54M | -0.40M |
| Total cash from financing activities | 0.20M | -3.27M | -1.42M | 243.04M | 121.42M |
| Change to operating activities | 1.40M | -3.38M | 0.66M | -1.49M | 0.78M |
| Net income | -74.73M | -69.39M | -36.60M | -33.74M | -22.80M |
| Change in cash | 14.29M | -23.91M | -2.85M | -96.50M | 126.35M |
| Begin period cash flow | 12.34M | 36.28M | 39.13M | 135.63M | 9.29M |
| End period cash flow | 26.63M | 12.38M | 36.28M | 39.13M | 135.63M |
| Total cash from operating activities | -53.89M | -57.24M | -44.95M | -35.62M | 7.99M |
| Issuance of capital stock | - | - | 0.11M | 238.50M | 122.23M |
| Depreciation | 4.12M | 7.20M | 3.41M | 2.69M | 1.68M |
| Other cashflows from investing activities | - | - | - | -300.55M | 0.00M |
| Dividends paid | - | - | - | - | 0.00M |
| Change to inventory | - | - | - | - | 0.00M |
| Change to account receivables | - | - | - | - | 0.00M |
| Sale purchase of stock | 0.20M | 0.21M | 0.11M | 238.50M | 122.23M |
| Other cashflows from financing activities | 0.13M | 0.21M | 43.52M | 4.54M | 121.81M |
| Change to netincome | 9.60M | 10.29M | 7.91M | 1.89M | 0.26M |
| Capital expenditures | 2.12M | 2.36M | 7.13M | 3.37M | 3.06M |
| Cash flows other operating | 5.88M | 3.99M | -21.47M | - | - |
| Cash and cash equivalents changes | 14.29M | -23.91M | -2.85M | - | - |
| Change in working capital | 3.73M | -5.34M | -19.68M | -6.46M | 28.85M |
| Stock based compensation | 9.51M | 10.29M | 7.91M | 1.89M | 0.26M |
| Other non cash items | 3.49M | 51.10M | 27.62M | -205.93M | -90.34M |
| Free cash flow | -56.00M | -59.60M | -52.09M | -38.99M | 4.93M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NXTC NextCure Inc |
-0.21 3.29% |
6.31 | - | - | 9.52 | 0.47 | 1.62 | 0.75 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
9000 Virginia Manor Road, Beltsville, MD, United States, 20705
240 399 4900
82
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael S. Richman MSBA | Co-Founder, CEO, Pres & Director | 1961 |
| Dr. Solomon Langermann Ph.D. | Chief Scientific Officer | 1960 |
| Dr. Han Myint FACP, M.D. | Chief Medical Officer | 1953 |
| Dr. Lieping Chen M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 1958 |
| Mr. Steven P. Cobourn CPA, CPA | Chief Financial Officer | 1963 |
| Dr. Timothy Mayer Ph.D. | Chief Operating Officer | 1965 |
| Mr. Sourav Kundu Ph.D. | Sr. VP of Devel. & Manufacturing | 1960 |
| Mr. Michael S. Richman MSBA | Co-Founder, CEO, President & Director | 1961 |
| Mr. Steven P. Cobourn CPA | Chief Financial Officer | 1963 |
| Mr. Kevin G. Shaw | General Counsel | 1974 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...